alpha-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial

Andrea Woltman, MJ (Martijn) ter Borg, RS Binda, Dave Sprengers, BME von Blomberg, RJ Scheper, K Hayashi, N Nishi, Andre Boonstra, Renate Molen, HLA Janssen

Research output: Contribution to journalArticleAcademicpeer-review

77 Citations (Scopus)


Background: The glycosphingolipid alpha-galactosylceramide (alpha-GalCer) is known to stimulate invariant natural killer T-cells (iNKTs) and is able to induce powerful antiviral immune responses. The present dose-escalating randomized placebo-controlled Phase I/II trial aimed to investigate antiviral activity and safety of alpha-GalCer as a novel class of treatment for chronic hepatitis B patients. Methods: Patients were randomly assigned to 0.1 mu g/kg (n=8), 1 mu g/kg (n=6) or 10 mu g/kg (n=6) alpha-GalCer or placebo (n=7) treatment. Results: Almost all alpha-GalCer-treated patients showed a rapid and strong decrease in natural killer T-cell (NKT) numbers. Patients with high baseline NKT numbers showed immune activation, including natural killer cell activation, increased serum turnout necrosis factor-alpha and interleukin-6 levels, and development of fever. Three patients demonstrated a transient decrease in hepatitis B virus (HBV) DNA. Only one alpha-GalCer-treated patient had a sustained decrease in HBV DNA at the end of follow-up. Four patients discontinued therapy because of fever shortly after drug administration. No significant side effects were observed. Conclusions: alpha-GalCer (0.1-10 mu g/kg) used as monotherapy for chronic hepatitis B infection resulted in a strong decrease of NKTs, but did not clearly affect HBV DNA and alanine aminotransferase levels. alpha-GalCer was poorly tolerated and is unlikely to be suitable as an alternative monotherapy to the current treatment regimen.
Original languageUndefined/Unknown
Pages (from-to)809-818
Number of pages10
JournalAntiviral Therapy
Issue number6
Publication statusPublished - 2009

Research programs

  • EMC MM-04-20-02-A

Cite this